New Approach in Delivering Chemotherapy: Locoregional Treatment for Recurrent Glioblastoma (rGBM)

Amerigo Boiardi, M. Eoli, A. Salmaggi, E. Lamperti, A. Botturi, G. Broggi, M. Bartolomei, A. Silvani

Research output: Contribution to journalArticle

Abstract

The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50% if results are evaluated in relation with the most frequent data of the literature.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalJournal of Experimental and Clinical Cancer Research
Volume22
Issue number4 SUPPL.
Publication statusPublished - Dec 2003

Fingerprint

Glioblastoma
Mitoxantrone
temozolomide
Drug Therapy
Radioimmunotherapy
Recurrence
Disease-Free Survival
Neoplasms
Appointments and Schedules
Therapeutics

Keywords

  • Glioblastoma recurrence
  • Local chemotherapy
  • Locoregional radioimmunotherapy
  • Mitoxantrone
  • Pegylated doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New Approach in Delivering Chemotherapy : Locoregional Treatment for Recurrent Glioblastoma (rGBM). / Boiardi, Amerigo; Eoli, M.; Salmaggi, A.; Lamperti, E.; Botturi, A.; Broggi, G.; Bartolomei, M.; Silvani, A.

In: Journal of Experimental and Clinical Cancer Research, Vol. 22, No. 4 SUPPL., 12.2003, p. 123-127.

Research output: Contribution to journalArticle

@article{8dba66db06524f1285dda9a14834788a,
title = "New Approach in Delivering Chemotherapy: Locoregional Treatment for Recurrent Glioblastoma (rGBM)",
abstract = "The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95{\%} of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50{\%} if results are evaluated in relation with the most frequent data of the literature.",
keywords = "Glioblastoma recurrence, Local chemotherapy, Locoregional radioimmunotherapy, Mitoxantrone, Pegylated doxorubicin",
author = "Amerigo Boiardi and M. Eoli and A. Salmaggi and E. Lamperti and A. Botturi and G. Broggi and M. Bartolomei and A. Silvani",
year = "2003",
month = "12",
language = "English",
volume = "22",
pages = "123--127",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - New Approach in Delivering Chemotherapy

T2 - Locoregional Treatment for Recurrent Glioblastoma (rGBM)

AU - Boiardi, Amerigo

AU - Eoli, M.

AU - Salmaggi, A.

AU - Lamperti, E.

AU - Botturi, A.

AU - Broggi, G.

AU - Bartolomei, M.

AU - Silvani, A.

PY - 2003/12

Y1 - 2003/12

N2 - The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50% if results are evaluated in relation with the most frequent data of the literature.

AB - The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50% if results are evaluated in relation with the most frequent data of the literature.

KW - Glioblastoma recurrence

KW - Local chemotherapy

KW - Locoregional radioimmunotherapy

KW - Mitoxantrone

KW - Pegylated doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=1842478671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842478671&partnerID=8YFLogxK

M3 - Article

C2 - 16767918

AN - SCOPUS:1842478671

VL - 22

SP - 123

EP - 127

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 4 SUPPL.

ER -